SNOA

MKT CAP:$2M

Sonoma Pharmaceuticals, Inc.

Market Cap

$2M

Healthcare·Drug Manufacturers - Specialty & Generic·🇺🇸 United States·NASDAQ

Healthcare·Drug·🇺🇸·NASDAQ

Stock Price

$1.14-$2.50 (-68.68%)

Apr 24, 2026

Company Details

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and interna...

CEO

Amy Trombly

IPO Date

Jan 25, 2007

Website

www.sonomapharma.com

Key Metrics TTM

Revenue

$14M

+20.0% YoY

Net Income

-$4M

EPS (Diluted)

-$4.06

Free Cash Flow

-$3M

Revenue / Share

$8.79

Gross Margin

36.2%

Operating Margin

-31.4%

Net Margin

-28.2%

FCF Margin

-17.7%

P/S

0.1x

P/E

—

Earnings Reports

Q1 2026

Aug 7, 2025

$4M+18.4%EPS -$0.76

FY 2025

Jun 17, 2025

$14M+12.2%EPS -$2.79

Q2 2025

Nov 7, 2024

$4M+31.1%EPS -$0.59

Q1 2025

Aug 8, 2024

$3MEPS -$1.34

FY 2024

Jun 17, 2024

$13M-4.0%EPS -$5.32

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 20	$4M	$2M	-$1M
Q3 21	$5M	$2M	-$138.0K
Q4 21	$2M	-$194.0K	-$3M
Q1 22	$4M	$1M	-$904.0K
Q2 22	$4M	$1M	-$964.0K
Q3 22	$3M	$1M	-$958.0K
Q4 22	$2M	$96.0K	-$3M
Q1 23	$4M	$2M	-$855.0K
Q2 23	$3M	$2M	-$731.0K
Q3 23	$3M	$831.0K	-$2M
Q4 23	$3M	$864.0K	-$1M
Q2 24	$3M	$990.0K	-$1M
Q4 24	$3M	$1M	-$1M
Q1 25	$3M	$1M	-$1M
Q2 25	$4M	$1M	-$850.0K
Q1 26	$4M	$1M	-$1M

Valuation

Quarter	P/S	P/E
Q3 20	0.1x	—
Q3 21	0.1x	—
Q4 21	0.1x	—
Q1 22	0.1x	—
Q2 22	0.1x	—
Q3 22	0.2x	—
Q4 22	0.2x	—
Q1 23	0.1x	—
Q2 23	0.2x	—
Q3 23	0.2x	—
Q4 23	0.1x	—
Q2 24	0.2x	—
Q4 24	0.2x	—
Q1 25	0.2x	—
Q2 25	0.1x	—
Q1 26	0.1x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 20	-$840.0K	-$849.0K
Q3 21	$746.0K	$669.0K
Q4 21	-$1M	-$1M
Q1 22	-$1M	-$1M
Q2 22	-$1M	-$1M
Q3 22	-$326.0K	-$327.0K
Q4 22	-$1M	-$1M
Q1 23	-$2M	-$2M
Q2 23	-$2M	-$2M
Q3 23	-$348.0K	-$379.0K
Q4 23	-$2M	-$3M
Q2 24	-$1M	-$1M
Q4 24	$152.0K	$155.0K
Q1 25	-$912.0K	-$917.0K
Q2 25	$354.0K	$328.0K
Q1 26	-$2M	-$2M

Capital Expenditures

Quarter	CapEx
Q3 20	$9.0K
Q3 21	$77.0K
Q4 21	$5.0K
Q1 22	$49.0K
Q2 22	$25.0K
Q3 22	$1.0K
Q4 22	$62.0K
Q1 23	$23.0K
Q2 23	$25.0K
Q3 23	$31.0K
Q4 23	$190.0K
Q2 24	$2.0K
Q4 24	$3.0K
Q1 25	$5.0K
Q2 25	$26.0K
Q1 26	$106.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 20	-16.8%	-27.9%
Q3 21	+12.6%	-28.4%
Q4 21	-52.0%	-20.7%
Q1 22	-22.1%	-23.7%
Q2 22	-14.8%	-14.4%
Q3 22	-41.2%	-23.9%
Q4 22	+6.5%	+7.8%
Q1 23	+8.1%	+5.4%
Q2 23	-11.0%	-13.7%
Q3 23	+1.4%	+23.8%
Q4 23	+31.2%	-22.3%
Q2 24	-31.4%	-18.6%
Q4 24	+3.2%	+19.4%
Q1 25	+15.2%	-4.5%
Q2 25	+18.7%	+6.4%
Q1 26	+47.0%	+29.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 20	$112.0K	2.5%
Q3 21	$93.0K	1.9%
Q4 21	$55.0K	2.5%
Q1 22	$59.0K	1.6%
Q2 22	$55.0K	1.5%
Q3 22	$56.0K	1.9%
Q4 22	$212.0K	9.2%
Q1 23	$214.0K	5.4%
Q2 23	$0	0.0%
Q3 23	$0	0.0%
Q4 23	$100.0K	3.3%
Q2 24	$130.0K	4.8%
Q4 24	$0	0.0%
Q1 25	$107.0K	3.2%
Q2 25	$14.0K	0.4%
Q1 26	$57.0K	1.4%

OpEx Breakdown

Quarter	R&D	SG&A
Q3 20	$248.0K	$3M
Q3 21	$33.0K	$2M
Q4 21	$130.0K	$2M
Q1 22	$84.0K	$2M
Q2 22	$10.0K	$2M
Q3 22	$26.0K	$2M
Q4 22	$4.0K	$3M
Q1 23	$206.0K	$2M
Q2 23	$200.0K	$2M
Q3 23	—	$3M
Q4 23	$201.0K	$2M
Q2 24	$536.0K	$2M
Q4 24	$409.0K	$2M
Q1 25	$470.0K	$2M
Q2 25	$506.0K	$2M
Q1 26	$594.0K	$2M

Revenue Segments

Quarter	Animal Care	Human Care	Other Sales	Service And Royalty	Product
Q3 21	$1M	$4M	$45.0K	—	—
Q1 22	$812.0K	$3M	—	$157.0K	—
Q2 22	$1M	$3M	—	$148.0K	—
Q3 22	$818.0K	$2M	—	$69.0K	—
Q4 22	$414.0K	$2M	—	—	—
Q2 24	$489.0K	$2M	—	$167.0K	—
Q1 25	—	—	—	—	$3M
Q2 25	$402.0K	$3M	—	$220.0K	—
Q1 26	—	—	—	—	$4M

Revenue by Geography

Quarter	Europe and Rest of the World	Latin America	United States
Q3 20	$1M	$988.0K	$2M
Q3 21	$2M	$1M	$2M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$7M	$0	$7M
Q1 23	$6M	$0	$6M
Q2 23	$3M	$0	$3M
Q3 23	$3M	$0	$3M
Q4 23	$4M	$0	$4M
Q1 24	$4M	$0	$4M
Q2 24	$2M	$0	$2M
Q3 24	$2M	$0	$2M
Q4 24	$3M	$0	$3M
Q1 25	$3M	$0	$3M
Q2 25	$4M	$0	$4M
Q3 25	$5M	$0	$5M
Q4 25	$5M	$0	$5M
Q1 26	$4M	$0	$4M
Q2 26	$3M	$0	$3M
Q3 26	$3M	$0	$3M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 20	150K	+13.9%	+54.5%
Q3 21	205K	+36.8%	+55.7%
Q4 21	209K	+1.6%	+56.1%
Q1 22	209K	+0.4%	+58.9%
Q2 22	234K	+12.0%	+56.3%
Q3 22	308K	+31.4%	+50.1%
Q4 22	277K	-10.1%	+32.9%
Q1 23	310K	+11.9%	+48.2%
Q2 23	310K	0.0%	+32.3%
Q3 23	311K	+0.2%	+0.9%
Q4 23	468K	+50.6%	+68.9%
Q2 24	516K	+10.4%	+66.5%
Q4 24	780K	+51.1%	+151.7%
Q1 25	851K	+9.1%	+174.0%
Q2 25	1M	+21.4%	+121.0%
Q1 26	2M	+58.7%	+217.8%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 20	$23.0K	191
Q3 21	$17.6K	280
Q4 21	$11.7K	185
Q1 22	$19.9K	185
Q2 22	$20.2K	185
Q3 22	$15.7K	185
Q4 22	$13.9K	165
Q1 23	$24.1K	165
Q2 23	$20.2K	165
Q3 23	$17.8K	165
Q4 23	$18.6K	162
Q2 24	$16.9K	162
Q4 24	$21.2K	162
Q1 25	$20.9K	162
Q2 25	$22.1K	162
Q1 26	$25.1K	160

Revenue / Employee